Theragnostics receives U.K. MHRA Innovation Passport

2022 02 11 17 17 9243 Business Lab Startup Team 400

Radiopharmaceuticals firm Theragnostics has been awarded an Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its THG-009 iodine-123 poly (ADP-ribose) polymerase inhibitor (PARPi) radiotherapeutic agent.

Theragnostics is developing the I-123 PARPi agent for treating primary and recurrent glioblastoma multiforme (GBM). The vendor said that its early nonclinical data showed promising results, supporting the progression of I-123 PARPi into a phase I clinical study for treating recurrent GBM.

The Innovation Passport, provided under the MHRA's Innovative Licensing and Access Pathway, is awarded by the agency to companies developing therapeutics for life-threatening or seriously debilitating conditions, Theragnostics said. In the next step of this regulatory pathway, a target development profile document will be prepared by the MHRA, the National Institute for Health and Care Excellence, and the Scottish Medicines Consortium.

Page 1 of 1250
Next Page